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E-mail address: oliver.werz@uni-tuebingen.de (O.Selective inhibition of pro-inﬂammatory prostaglandin (PG)E2 formation via microsomal PGE2 synthase-1
(mPGES-1) might be superior over inhibition of all cyclooxygenase (COX)-derived products by non-ste-
roidal anti-inﬂammatory drugs (NSAIDs) and coxibs. We recently showed that benzo[g]indol-3-carboxyl-
ates potently suppress leukotriene biosynthesis by inhibiting 5-lipoxygenase. Here, we describe the
discovery of benzo[g]indol-3-carboxylates as a novel class of potent mPGES-1 inhibitors (IC50P 0.1 lM).
Ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate (compound 7a) inhibits human
mPGES-1 in a cell-free assay (IC50 = 0.6 lM) as well as in intact A549 cells (IC50 = 2 lM), and suppressed
PGE2 pleural levels in rat carrageenan-induced pleurisy. Inhibition of cellular COX-1/2 activity was signif-
icantly less pronounced. Compound 7a signiﬁcantly reduced inﬂammatory reactions in the carrageenan-
induced mouse paw edema and rat pleurisy. Together, based on the select and potent inhibition of
mPGES-1 and 5-lipoxygenase, benzo[g]indol-3-carboxylates possess potential as novel anti-inﬂamma-
tory drugs with a valuable pharmacological proﬁle.
 2009 Elsevier Ltd. All rights reserved.1. Introduction
Prostaglandin (PG)E2 is synthesized from arachidonic acid (AA)
by the concerted action of cyclooxygenases (COX) and PGE2 syn-
thases (PGES). As a key mediator in inﬂammation, PGE2 induces fe-
ver and pain via speciﬁc G-protein coupled receptors EP1-4.1
Different terminal isoforms of PGES exist, and co-expression stud-
ies have indicated preferential functional coupling between COX
and PGES isoenzymes.2 Thus, the cytosolic PGE2 synthase (cPGES)
generally receives its substrate PGH2 from COX-1 and the micro-
somal PGE2 synthase-1 (mPGES-1) from COX-2.2,3 cPGES is consti-
tutively expressed and primarily provides PGE2 for homeostasis,
whereas expression of mPGES-1 (together with COX-2) is strongly
induced by pro-inﬂammatory stimuli (e.g., interleukin (IL)-1b)
resulting in increased PGE2 formation during inﬂammation.4 Re-
sults from mPGES-1 inhibitor and knockout studies suggest bene-
ﬁcial effects of targeting mPGES-1 as compared to inhibition of
COX-1 and -2 by non-steroidal anti-inﬂammatory drugs (NSAIDs)
or exclusively COX-2 by coxibs.5 For example, the selective andll rights reserved.
x: +49 7071 294565.
Werz).orally active mPGES-1 inhibitor 2-(6-chloro-1H-phenanthro[9,10-
d]imidazol-2-yl)isophthalonitrile (MF63) is effective in inhibiting
LPS-induced pyresis, hyperalgesia, and iodoacetate-induced osteo-
arthritic pain in guinea pig and in knock-in mice expressing human
mPGES-1.6 Gastrointestinal toxicity, symptomatic for NSAIDs, was
observed neither in the knock-in mouse model nor in non-human
primates. mPGES-1-deﬁcient mice develop normally but exhibit
reduced inﬂammatory responses7 and show no fever in response
to lipopolysaccharide (LPS).8 In contrast to coxibs, cardiovascular
functions seem not impaired, since mPGES-1 deletion neither
affected thrombogenesis nor blood pressure in mice.9
The number of mPGES-1 inhibitors described in the literature is
limited. Compound 1 (MK-886 (3-[1-(4-chlorobenzyl)-3-t-butyl-
thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoicacid, IC50 = 2 lM)
and structural derivatives thereof potently inhibit cell-free mPGES-
1, but they suffer from plasma protein binding and loose potency in
cell-based assays or in in vivo animalmodels.10,11 On the other hand,
phenanthrene imidazoles,12 a-alkyl-substituted pirinixic acid
derivatives,13 and 2-[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-
2,3-dihydro-1H-pyrrolizin-5-yl] acetic acid (licofelone,14 currently
undergoing phase III trials for therapy of osteoarthritis) inhibit
mPGES-1 in cell-free assays and in intact cells or in human whole
A. Koeberle et al. / Bioorg. Med. Chem. 17 (2009) 7924–7932 7925blood. Moreover, diverse natural compounds including the acylphl-
oroglucinols myrtucommulone fromMyrtus communis and garcinol
from Guttiferae species or the polyphenolic curcumin from Curcuma
longa suppressed PGE2 formation in whole blood, which could be
attributed to direct inhibition of mPGES-1.15–17
We have recently shown that 5-lipoxygenase (LO) is potently
inhibited by diverse indol-3-carboxylates.18,19 Here, we show that
benzo[g]indol-3-carboxylates potently inhibit mPGES-1 and thus
represent a novel class of dual 5-LO/mPGES-1 inhibitors. Using
A549 lung carcinoma cells, we demonstrate that select compounds
also suppress PGE2 formation in intact cells without marked con-
comitant inhibition of the cellular synthesis of other COX-1/2 prod-
ucts. Finally, signiﬁcantly reduced PGE2 levels in pleural exudates of
carrageenan-treated rats demonstrate efﬁcacy in vivo after intra-
peritoneal administration of the benzo[g]indol-3-carboxylate 7a.
2. Results and discussion
2.1. Screening of indole-3-carboxylates as direct mPGES-1
inhibitors
Upon stimulation with IL-1b (1 ng/ml, 72 h), A549 cells highly
express mPGES-1, and after subcellular fractionation, mPGES-1 isTable 1
Inhibition of PGE2 formation in microsomal preparations of IL-1b-stimulated A549 cells a
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6found in the microsomal fraction.4 In order to investigate whether
the test compounds inhibit the catalytic activity of mPGES-1,
microsomal preparations of IL-1b-stimulated A549 cells (5 lg/
100 ll) were pre-incubated with the test compounds for 15 min
and assayed for suppression of enzymatic PGE2 formation from
PGH2 at standardized assay conditions (i.e., potassium phosphate
buffer 0.1 M, pH 7.4, 20 lM PGH2 as substrate, and 2.5 mM gluta-
thione as co-substrate) modiﬁed according to Jakobsson et al.4
Formed PGE2 was quantiﬁed by RP-HPLC. The cyclic peroxide
PGH2 is highly reactive and spontaneously degrades to PGF2a,
PGD2, and PGE2 in aqueous solutions within a few minutes.20,21
Consequently, the enzymatic assay was performed at 4 C for
1 min in order to avoid non-enzymatic conversion of PGH2 to
PGE2. The indole derivative 1, a well-recognized inhibitor of
mPGES-1,10 was used as reference compound. In accordance with
the literature,11,14,22 compound 1 concentration-dependently
(0.1–10 lM) blocked PGE2 formation with an IC50  2 lM showing
maximal inhibition (82 ± 3%) at 30 lM.
The test compounds (Table 1) were ﬁrst analyzed for inhibition
of PGE2 formation in the cell-free assay described above at 10 lM.
For compounds that achieved more than 50% inhibition at 10 lM,
IC50 values were assessed. Compound 2 (ethyl 2-[(3-chloro-
phenyl)amino]-5-hydroxy-1H-indole-3-carboxylate) that showednd of isolated ovine COX-1 and human recombinant COX-2
PGES-1 activity
percentage of control)
t 10 lM
IC50 (lM)
mPGES-1
COX activity (percentage of
control) at 10 lM
COX-1 COX-2
3 ± 2*** 2a 42 ± 7**,b 79 ± 8b
3 ± 8 n.d.c n.d. n.d.
5 ± 10*** n.d. n.d. n.d.
5 ± 6*** n.d. n.d. n.d.
(continued on next page)
Table 1 (continued)
Compound Structure mPGES-1 activity
(percentage of control)
at 10 lM
IC50 (lM)
mPGES-1
COX activity (percentage of
control) at 10 lM
COX-1 COX-2
5 R1 =  
R2 = -4-biphenyl  
Cl
25 ± 2*** 3.1 n.i.d n.i.
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7c
R1 =  
Br
R2, R3, R4 = -H 
14 ± 5*** 0.2 82 ± 6 74 ± 10
7d
R1 =  
OMe
R2, R3, R4 = -H 
9 ± 1*** 0.6 89 ± 10 n.i.
8
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46 ± 6*** 9.2 n.d. n.d.
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Table 1 (continued)
Compound Structure mPGES-1 activity
(percentage of control)
at 10 lM
IC50 (lM)
mPGES-1
COX activity (percentage of
control) at 10 lM
COX-1 COX-2
11
R1 =  
Cl
R2, R3, R4 = -H 
57 ± 6*** n.d. n.d. n.d.
12 R1 =  
Cl
R2 = -benzyl 
R3, R4 = -H 
n.i. n.d. n.d. n.d.
13 R1 =  
Cl
R2 = -H 
R3, R4 = -OMe 
30 ± 2*** 1.7 n.i. n.i.
14 R1 =  
Cl
R2, R4 = -H 
R3 = -phenyl 
28 ± 5*** 2.8 66 ± 8 n.i.
Mean values (n = 3–5) and standard error estimates are given; *p <0.05; **p <0.01; ***p <0.001.
a Ref. 14.
b Published by Koeberle et al.41
c n.d. = not determined.
d n.i. = no inhibition.
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assays (IC50 = 0.3 lM)18 was used as lead structure (Table 1). Only a
moderate inhibition of mPGES-1 activity was observed at 10 lM
(17 ± 8%). Exchange of the nitrogen by a methylene moiety (3)
and elongation by another methylene group (4) slightly improved
the potency. Removal of the 5-hydroxy moiety in 2 or replacement
by chlorine had no marked impact on the inhibition of mPGES-1
activity (data not shown). It has been shown that bulky hydropho-
bic substituents (i.e., biphenyl moieties) in mPGES-1 inhibitors like
in derivatives of 111 or in pirinixic acid derivatives13 strongly en-
hance the potency. These substituents may bind to a large hydro-
phobic pocket formed by Val37, Val128, and Thr131 in the
enzyme.23 In fact, when a 4-biphenyl residue at 7-position of 2
was introduced (5), the potency was signiﬁcantly increased
(IC50 = 3.1 lM). Enlargement of the hydrophobic core structure
by annelation of benzene to the indole of 2, yielding the corre-
sponding benzo[g]indole derivate 6, even led to an IC50 of
1.6 lM. Such benzo[g]indole-3-carboxylates were also found to
be potent inhibitors of 5-LO being superior over the corresponding
compounds lacking the annelated benzene.19 Therefore, we further
explored benzo[g]indole-3-carboxylates in order to obtain potent
mPGES-1 inhibitors.
The exchange of the nitrogen in 2-position of 6 by a methylene
group, leading to 7a, further enhanced the potency with essentially
complete suppression of PGE2 formation at 10 lM (97 ± 2% inhibi-
tion), and the IC50 value was determined at 0.6 lM. Replacement of
chlorine in 7a by ﬂuorine (compound 7b), bromine (compound 7c),
or a methoxy group (7d) was tolerated and yielded somewhat low-
er IC50 values, although the effectiveness at 10 lM was not im-proved over 7a. Variation of the positioning of the chlorine in the
benzyl ring of 7a to para (compound 8) was detrimental, whereas
ortho-positioning (compound 9) led to an IC50 = 0.1 lM and strong
inhibition at 10 lM (86 ± 0.4%). When the distance between the
phenyl ring in 2-position and the indole in 7a was altered, either
by direct connection of the 3-chlorophenyl residue (10) or elonga-
tion by insertion of another methylene moiety (11), the potency
was markedly lost, and the IC50 values shifted to approx. 9 lM
and >10 lM, respectively. A total loss of activity was evident, when
the indole nitrogen of 7a was substituted by a benzyl group (12),
and also the corresponding benzyl carboxylate of 7a was clearly
inferior (42 ± 8% inhibition at 10 lM, not shown). Thus, the hetero-
cyclic nitrogen and the carboxylate group were excluded from fur-
ther structural optimization. Further enlargement of the
hydrophobic core structure of 7a by annelation of a 2,3-dime-
thoxybenzene moiety (13) to the indole, instead of benzene, or
phenyl substitution at 8-position of the benzo[g]indole (14) also
failed to improve the efﬁciency and led to compounds with higher
IC50 values. Together, we identiﬁed 2-benzyl-substituted ethyl 5-
hydroxy-benzo[g]indole-3-carboxylates as direct and potent inhib-
itors of mPGES-1.
2.2. Analysis of the inhibition of COX isoenzymes by indole-3-
carboxylates
Using puriﬁed ovine COX-1 and puriﬁed human recombinant
COX-2, we determined the effects of the test compounds on iso-
lated COX isoenzymes. COX-1/2 was pre-incubated with the test
compounds at 10 lM for 5 min, AA (5 lM for COX-1, 2 lM for
7928 A. Koeberle et al. / Bioorg. Med. Chem. 17 (2009) 7924–7932COX-2) was added, and after 5 min at 37 C, the formation of 12(S)-
hydroxy-5-cis-8,10-trans-heptadecatrienoic acid (12-HHT), the
major COX-1/2-derived product under these experimental condi-
tions,14 was determined. Indomethacin (10 lM) and celecoxib
(5 lM), used as controls, inhibited 12-HHT formation by 95±0.2%
and 70±11%, respectively. The benzo[g]indole-carboxylate 7a sig-
niﬁcantly suppressed both COX-1 and -2 activity. Inhibition of
COX isoenzymes was strongly impaired by replacement of chlorine
in 7a by ﬂuoro (7b), bromo (7c) or methoxy substituents (7d) and
by shifting the meta-chloro substituent to para (8) or ortho (9) po-
sition. Also the 7-biphenyl-substituted indole-3-carboxylate 5 and
the 7- and/or 8-substituted benzo[g]indole-3-carboxlates 13 and
14 failed to signiﬁcantly affect COX-1/2 activity.
2.3. Characterization of mPGES-1 inhibition by benzo[g]indole-
3-carboxylates
To investigate whether the benzo[g]indole-3-carboxylates inhi-
bit mPGES-1 in a reversible or irreversible manner, we performed
wash-out experiments. To this aim, 10-fold concentrated micro-
somal preparations of A549 cells (50 lg/100 ll) were pre-incu-
bated with 3 lM compound 1 (a reversible inhibitor14 used as
control) or 7a. After 15 min, these samples were diluted 10 times
to obtain an inhibitor concentration of 0.3 lM (labeled ‘3(0.3)’)
and 50 lg/1000 ll of microsomes, and to an aliquot of 100 ll
thereof, PGH2 was added in order to initiated PGE2 formation. For
comparison, 5 lg/100 ll of microsomal preparations were directly
pre-incubated with 0.3 lM (labeled ‘0.3’) or 3 lM (labeled ‘3’)
compounds (no dilution).
Both compounds 1 and 7a only marginally reduced PGE2 syn-
thesis at 0.3 lM, whereas a potent mPGES-1 inhibition was evident
at 3 lM (Fig. 1A). Upon 10-fold dilution of the samples containing
3 lM of 7a or of 1, the suppressed PGE2 synthesis was restored,
implying a reversible mode of inhibition.
The potency of compound 1 to inhibit mPGES-1 is independent
of the substrate concentration (i.e., 1–20 lM PGH2), implying a
non-competitive mode of action.14 Similarly, inhibition of
mPGES-1 activity by 7a in the cell-free assay was not different at
high (20 lM PGH2) or low (1 lM PGH2) substrate concentration,
concluding that also benzo[g]indole-3-carboxylates may act at
physiological concentrations of PGH2 in a substrate concentra-
tion-independent manner (Fig. 1B).w/
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Figure 1. The benzo[g]indol-3-carboxylate 7a inhibits mPGES-1 in a reversible and su
stimulated A549 cells (50 lg/100 ll) were pre-incubated with 3 lM compound 1 or 7
concentration of 0.3 lM (labeled ‘3(0.3)’) and 50 lg/1000 ll of microsomes, and to an
comparison, we directly pre-incubated microsomal preparations (5 lg/100 ll) for 15 min
(DMSO), and then, 20 lM PGH2 was added (no dilution). Then, PGE2 formation was ana
vehicle (0.1% DMSO) control, ANOVA + Tukey HSD post-hoc tests. (B) The potency of 7a
PGH2, the amount of PGE2 was below the detection limit of the HPLC and was thus quan
Data are given as mean ± SE, n = 3–4.2.4. Benzo[g]indole-3-carboxylates selectively inhibit PGE2
formation in cell-based assays
Potent inhibition of mPGES-1 and/or COX-1/2 under cell-free
conditions must not necessarily result in efﬁcient suppression
of cellular prostanoid formation. In fact, compound 1 and related
derivatives with high potency on isolated mPGES-1 failed to efﬁ-
ciently inhibit PGE2 biosynthesis in intact A549 cells or in hu-
man whole blood.11 IL-1b-stimulated A549 cells highly express
COX-2 and mPGES-14, whereas COX-1 cannot be detected.24
Accordingly, PGE2 formation in A549 cells depends on the con-
certed action of the functionally coupled enzymes COX-2 and
mPGES-1. Nevertheless, other PGE2 synthases, namely mPGES-2
and cPGES (essentially coupled to COX-1) may still participate
to a minor extent. After pre-incubation of intact IL-1b-stimulated
A549 cells with either 6, 7a, or 9, cells were activated by 2.5 lM
Ca2+ ionophore A23187. Exogenous AA (1 lM AA and 18.4 kBq
[3H]AA) was provided to circumvent the need for release of
endogenous AA and thus to exclude possible effects on AA-
releasing PLA2 enzymes. The COX-2 selective celecoxib and com-
pound 1 were used as controls. In agreement with previous
studies,14 PGE2 formation was almost completely abolished by
5 lM celecoxib (not shown), whereas 37 ± 6% PGE2 was still pro-
duced in the presence of 30 lM compound 1. As shown in Figure
2A, compounds 6 and 7a concentration-dependently suppressed
PGE2 formation with an IC50 of 7.9 and 2.0 lM, respectively.
The ortho-chlorobenzyl-substituted 9 was less potent with an
IC50 of 20.5 lM in intact A549 cells (Fig. 2A), although it dis-
played the lowest IC50 value (i.e., 0.1 lM) of all tested com-
pounds in the cell-free assay. Similarly, compound 9 was less
potent to inhibit 5-LO in intact neutrophils (IC50 = 1.2 lM) versus
cell-free assays (IC50 = 0.097 lM), while the difference between
the corresponding values for compound 7a was less pronounced
(IC50 = 0.23 and 0.086 lM in neutrophils and cell-free assay,
respectively).19 As observed before with other mPGES-1 inhibi-
tors, PGE2 formation was not completely blocked by the benzo[-
g]indole-3-carboxylates, and a residual PGE2 formation of
approx. 35–40% still remained. Since 7a already reduced PGE2
synthesis by 65 ± 8% at 3 lM without further inhibition at 10
or 30 lM, the remaining PGE2 formation is presumably mPGES-
1-independent and does not originate from an incomplete inhibi-
tion of mPGES-1 activity.B
comp. 7a [µM]
0 0.1 0.3 1
PG
E 2
 fo
rm
at
io
n
(p
er
ce
nt
ag
e 
of
 c
on
tr
ol
)
0
25
50
75
100 20 µM PGH2
1 µM PGH2
bstrate concentration-independent manner. (A) Microsomal preparations of IL-1b-
a for 15 min at 4 C. The sample was then diluted 10-fold to obtain an inhibitor
aliquot of 100 ll thereof, PGH2 (20 lM) was added to initiate PGE2 formation. For
with 0.3 lM (labeled ‘0.3’) or 3 lM (labeled ‘3’) compound 1 or 7a or with vehicle
lyzed as described in the text. Data are given as mean ± SE, n = 3–4, *p <0.05 versus
for mPGES-1 inhibition was compared at 1 and 20 lM PGH2 as substrate. For 1 lM
tiﬁed by use of a PGE2 High Sensitivity EIA Kit according to manufacturer’s protocol.
compound [µM]
0 1 3 10 33
0 1 3 10 33
PG
E 2
 fo
rm
at
io
n
(p
er
ce
nt
ag
e 
of
 c
on
tr
ol
)
0
25
50
75
100 67a
9
***
***
******
*
compound [µM]
1 α
 fo
rm
at
io
n
6-
ke
to
 P
G
F
(p
er
ce
nt
ag
e 
of
 c
on
tr
ol
)
0
25
50
75
100
125
6
7a
9
compound [µM]
0 1 10 30
12
-H
H
T 
fo
rm
at
io
n
(p
er
ce
nt
ag
e 
of
 c
on
tr
ol
)
0
25
50
75
100
6
7a
9
B
C
A
*
***
***
**
***
Figure 2. Effects of benzo[g]indole-3-carboxylates on the formation of prostanoids
in intact cells. (A) PGE2 formation. IL-1b-stimulated A549 cells were pre-incubated
with test compounds or vehicle (DMSO) for 10 min, then, cellular PGE2 synthesis
was elicited by addition of 2.5 lM A23187 plus 1 lM AA and [3H]AA (18.4 kBq).
After 15 min, formed [3H]PGE2 was analyzed by RP-HPLC and liquid scintillation
counting as described in Section 4. (B) 6-Keto PGF1a formation. IL-1b-stimulated
A549 cells (106/ml) were pre-incubated with the indicated test compounds or
vehicle (DMSO) for 15 min prior to addition of 30 lM AA. After 15 min at 37 C, the
amount of 6-keto PGF1a was assessed by ELISA as described in Section 4. Celecoxib
(5 lM) was used as control (70 ± 11% inhibition). (C) 12-HHT formation. Freshly
isolated human platelets (108/ml) were pre-incubated with the test compounds or
vehicle for 5 min prior to stimulation with AA (5 lM). After 5 min at 37 C, the
formation of 12-HHT was determined by RP-HPLC as described in Section 4.
Indomethacin (10 lM) was used as control (95 ± 0.2% inhibition). Data are given as
mean ± SE, n = 3–5, **p <0.01 or ***p <0.001 versus vehicle (0.1% DMSO) control,
ANOVA + Tukey HSD post-hoc tests.
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ance of COX-derived prostanoids such as PGI2, PGD2, and TxA2 that
possess important protective physiological functions in the cardio-
vascular system and in immunoregulation.1 Notably, certain
benzo[g]indol-3-carboxylates (e.g., compound 7a) possess an
inhibitory potential on COX enzymes in cell-free assays. To evalu-
ate whether they can affect cellular prostanoid formation at the
level of COX enzymes, we analyzed in parallel the formation of
6-keto PGF1a, the stable metabolite of PGI2, by ELISA as a biological
parameter of COX-2 activity. In fact, formation of 6-keto PGF1awas
not signiﬁcantly suppressed by 6 or 9 and also not by 7a, up to
30 lM (Fig. 2B). Celecoxib (5 lM) efﬁciently reduced 6-keto PGF1a
formation by 70 ± 11% under these conditions.
For analysis of the effects of benzo[g]indole-3-carboxylates on
cellular COX-1 activity, freshly isolated human platelets (supple-
mented with 5 lM exogenous AA) were used. Platelets are a rich
source of COX-1, and are generally applied in cell-based models
to assess inhibition of COX-1 in a biological environment.25 Plate-
lets were pre-incubated with the test compounds prior to addition
of 5 lM AA, and 12-HHT, the major COX-1 product formed under
these conditions, was analyzed by RP-HPLC. Indomethacin
(10 lM) was used as control and potently inhibited 12-HHT forma-
tion (95 ± 0.2%). In contrast, 6 and 7a moderately suppressed 12-
HHT formation at 10 lM (by 31 ± 3% and 43 ± 11%, respectively),
and no signiﬁcant effect was observed for 9 up to 30 lM (
Fig. 2C). Together, one may conclude that the observed inhibition
of cellular PGE2 by the benzo[g]indole-3-carboxylates cannot be
attributed to an interference with PGH2 formation, and thus,
COX-1 and -2 as possible targets in intact cells are unlikely.
2.5. Anti-inﬂammatory effectiveness of the benzo[g]indole-3-
carboxylate 7a, and inhibition of PGE2 biosynthesis in vivo
Because 7a was most efﬁcient to inhibit PGE2 formation in in-
tact A549 cells among the benzo[g]indol-3-carboxylates tested
(see Fig. 2A) and also potently suppressed leukotriene (LT)B4 for-
mation in cell-based models,19 its anti-inﬂammatory effectiveness
in vivo was evaluated in two well-established animal models of
inﬂammation, the carrageenan-induced mouse paw edema and
the carrageenan-induced pleurisy in rats. During paw edema for-
mation, PGE2 levels are signiﬁcantly elevated,26,27 and COX-inhibi-
tors were shown to prevent the inﬂammatory response.28 Also in
the pleurisy model, PGE2 essentially contributes to the early
inﬂammatory response following carrageenan stimulation.29,30
For analysis of the effects of 7a on mouse paw edema, the com-
pound (0.25, 1, and 4 mg/kg) was administered intraperitoneally
(ip) 30 min prior to injection of carrageenan into the mouse paw.
The increase in paw volume (vehicle ip treatment) reached a max-
imum at 4 h post-carrageenan treatment (Fig. 3). In fact, in mice
treated with 0.25, 1, and 4 mg/kg 7a, the peak of the response to
carrageenan at 4 h was reduced by 37%, 53%, and 61%, respectively.
Indomethacin (5 mg/kg, ip), used as reference, caused 57% inhibi-
tion (Fig. 3).
In the rat pleurisy model, ip treatment of rats with 4 mg/kg of
7a, 30 min prior to carrageenan administration, reduced the
inﬂammatory reaction (measured as exudate volume and inﬂam-
matory cell numbers in the pleural exudates) as described before19
(Table 2). Indomethacin (5 mg/kg, ip) reduced exudate formation
to a similar degree as 7a but was somewhat more efﬁcient in
reducing cell inﬁltration. In agreement with the results from intact
A549 cells, 7a signiﬁcantly lowered the pleural PGE2 levels but had
only a small and non-signiﬁcant effect on 6-keto PGF1a levels,
excluding a general interference with the biosynthesis of all PGs
or an effect at the level of COX enzymes. Indomethacin was consid-
erably more efﬁcient in lowering PGE2 levels but also blocked for-
mation of 6-keto PGF1a (Table 2). As reported before, 7a reduced
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Figure 3. Effects of the benzo[g]indole-3-carboxylate 7a on carrageenan-induced
mouse paw edema. Mice (n = 10 for each experimental group) were treated ip with
0.25, 1, and 4 mg/kg 7a, 5 mg/kg indomethacin (indo), or vehicle (2% DMSO) 30 min
before carrageenan subplantar injection. Data are given as mean ± SE, *p <0.05, **p
<0.01 or ***p <0.001 versus vehicle (DMSO 2%) control, ANOVA + Tukey HSD post-
hoc tests.
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suppression of LTB4 and PGE2 may contribute to the anti-inﬂam-
matory effect. Indomethacin, in contrast, did not suppress LTB4 lev-
els (Table 2), which precludes that general anti-inﬂammatory
effects (due to suppression of PGE2 formation by 7a) are responsi-
ble for the reduction of LTB4 levels. In conclusion, our data support
the anti-inﬂammatory effectiveness of 7a in living animals and
provide evidence for a selective suppression of PGE2 in vivo with-
out signiﬁcantly affecting the biosynthesis of PGI2.
The current therapeutic application of NSAIDs such as aspirin or
indomethacin suffers from gastrointestinal and renal side effects
due to the overall suppression of COX-derived prostanoid biosyn-
thesis. COX-2 selective coxibs have been designed lacking gastroin-
testinal toxicity, though they increase the cardiovascular risk.1
Knockout experiments and in vivo studies suggest that selective
inhibitors for mPGES-1 may achieve the therapeutic efﬁciency of
NSAIDs while circumventing their adverse events at the same
time.31 Moreover, dual inhibition of the PG and the LT synthetic
pathway might be of advantage in terms of higher anti-inﬂamma-
tory efﬁcacy on one hand and in terms of lower side effects on
the other.32 In particular, dual PG/LT synthetic pathway inhibitors
almost completely diminished gastric toxicity.33 Although the
underlying mechanism is not completely understood, inhibition
of LT formation in addition to repressing PGE2 seemingly possesses
advantages compared to single interference. For example, licofe-
lone blocks the biosynthesis of both PGE2 and LTs34 by inhibiting
mPGES-114 and the 5-LO-activating protein (FLAP),35 respectively,
and showed potent anti-inﬂammatory efﬁcacy in clinical trials
and animal studies with low gastric side effects36 and even beneﬁ-
cial cardiovascular properties.37 Unfortunately, mice deﬁcient in
both mPGES-1 and 5-LO (or FLAP) have not been created yet, but
such animalsmight certainly allow additional insights into the suit-
ability of the ‘dual inhibition concept’.Table 2
Effect of 7a on carrageenan-induced pleurisy in rats and pleural prostanoid levels
Treatment Exudate volume (ml) Inﬂammatory cells 
Vehicle 0.48 ± 0.08a 46.67 ± 3.53a
Compd 7a (4 mg/kg) 0.11 ± 0.0026***,a 28 ± 6.83*,a
Indomethacin (5 mg/kg) 0.14 ± 0.027***,a 18 ± 2.5***,a
Thirty minutes before intrapleural injection of carrageenan, rats (n = 10 for each experi
(DMSO 4%). Exudate volume, PGE2, 6-keto PGF1a, and LTB4 levels as well as inﬂammatory
Mean values (n = 3-5) and standard error estimates are given; *p <0.05; **p <0.01; ***p
a Published by Karg et al.193. Conclusion
In summary, we have reported the discovery of benzo[g]indole-
3-carboxylates as novel class of mPGES-1 inhibitors. Members of
this structural class are able to completely inhibit mPGES-1 activity
in cell-free assays at 10 lM (7a) and exhibit IC50 values of 0.1 lM
(9). We found that ortho-, meta-, or para-halogenated benzyl-sub-
stituents in 2-position of the indole led to a strong potency to-
wards mPGES-1. In contrast to the SARs regarding 5-LO, either
shortening or elongation of the distance between the indole and
the halogenated aryl moiety clearly diminished the potency. Also,
benzyl substitution of the indole nitrogen or benzyl esteriﬁcation
instead of ethyl was clearly detrimental. Selected compounds
(i.e., 6, 7a, and 9) from the benzo[g]indole-3-carboxylate series
showed marked inhibition of PGE2 formation in intact (A549) cells
(7a, IC50 = 2 lM), and compound 7a also reduced PGE2 levels
in vivo, accompanied by high anti-inﬂammatory efﬁcacy. Although
7a inhibited the activities of isolated COX-1/2, inhibition of cellular
COX-1/2 product formation was considerably less pronounced,
suggesting a selective interference with mPGES-1. It is remarkable
that the benzo[g]indole-3-carboxylate 7a combines strong inhibi-
tion of mPGES-1 with potent suppression of cellular 5-LO product
formation (IC50 = 0.23 lM) by direct inhibition of 5-LO
(IC50 = 0.086 lM).19 Such a dual inhibition may be valuable regard-
ing the anti-inﬂammatory efﬁcacy but also in terms of lower gas-
tric toxicity versus NSAIDs. Moreover, the failure of 7a to abolish
PGI2 biosynthesis, reﬂected by the failure to repress 6-keto PGF1a
formation in intact A549 cells or in the pleurisy model, proposes
a lower cardiovascular risk as compared to selective COX-2 inhib-
itors. The numerous encouraging results obtained in animal stud-
ies and clinical trials with the dual PG and LT synthesis inhibitor
licofelone38 are tempting to deduce similar or even improved prop-
erties for select benzo[g]indole-3-carboxylates. Future studies
addressing their anti-inﬂammatory effectiveness in other species
and additional models but also evaluation of the gastric toxicity
and cardiovascular risk as well as general toxicity will reveal the
therapeutic potential of (these drug-like) benzo[g]indole-3-
carboxylates.
4. Experimental
4.1. Compounds
Compounds 2–14 were synthesized as previously reported.18,19
All structures were conﬁrmed by 1H and 13C NMR, infrared spec-
troscopy as well as by mass spectrometry (ESI-), and the purity
(>98%) was checked by combustion analysis as described.19
4.2. Assay systems
4.2.1. Materials
The anti-6-keto PGF1a antibody was a generous gift by Dr. T.
Dingermann (University of Frankfurt, Germany). Materials used:
DMEM/high glucose (4.5 g/l) medium, penicillin, streptomycin,106 PGE2 (ng/rat) 6-Keto PGF1a (ng/rat) LTB4 (ng/rat)
2.79 ± 0.39 3.00 ± 1.02 1.17 ± 0.21a
1.30 ± 0.19** 2.02 ± 0.64 0.60 ± 0.096*,a
0.33 ± 0.04*** 0.018 ± 0.007** 1.02 ± 0.19
mental group) were treated ip with 4 mg/kg 7a, 5 mg/kg indomethacin, or vehicle
cell accumulation in the pleural cavity were assessed 4 h after carrageenan injection.
<0.01 versus vehicle.
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PGB1, MK-886, 6-keto PGF1a and LTB4 enzyme immunoassays, Cay-
man Chemical (Ann Arbor, MI); [5, 6, 8, 9, 11, 12, 14, 15-3H] arachi-
donic acid ([3H]AA), BioTrend Chemicals GmbH (Cologne,
Germany); Ultima GoldTM XR, Perkin–Elmer (Boston, MA). For ani-
mal studies, 7a and indomethacin (1-(4-chlorobenzoyl)-5-meth-
oxy-2-methyl-1H-indole-3-acetic acid) were dissolved in DMSO
and diluted with saline achieving a ﬁnal DMSO concentration of
2–4%. [3H]-PGE2 was from Perkin–Elmer Life Sciences (Milan, Italy)
and PGE2 antibody from Sigma–Aldrich (Milan, Italy). All other
chemicals were obtained from Sigma–Aldrich (Deisenhofen, Ger-
many) unless stated otherwise.
4.2.2. Cells and cell viability assay
A549 cells were cultured in DMEM/high glucose (4.5 g/l) med-
ium supplemented with heat-inactivated fetal calf serum (10%, v/
v), penicillin (100 U/ml), and streptomycin (100 lg/ml) at 37 C
in a 5% CO2 incubator. After 3 days, conﬂuent cells were detached
using 1 trypsin/EDTA solution and reseeded at 2  106 cells in
20 ml medium in 175 cm2 ﬂasks. Cell viability was measured using
the colorimetric MTT dye reduction assay. A549 cells (4  104
cells/100 ll medium) were plated into a 96-well microplate and
incubated at 37 C and 5% CO2 for 16 h. Then, test compounds
(30 lM, each) or solvent (DMSO, never exceeding a ﬁnal concentra-
tion of 0.3%) were added, and the samples were incubated for an-
other 5 h. MTT (20 ll, 5 mg/ml) was added and the incubations
were continued for 4 h. The formazan product was solubilized with
SDS (10%, m/v in 20 mM HCl) and the absorbance of each sample
was measured at 595 nm relative to the absorbance of vehicle
(DMSO)-treated control cells using a multiwell scanning spectro-
photometer (Victor3 plate reader, Perkin–Elmer, Rodgau-Jueges-
heim, Germany). Neither 6 nor 7a signiﬁcantly reduced cell
viability (data not shown), excluding possible acute cytotoxic
effects of the compounds in the cellular assays.
4.2.3. Induction of mPGES-1 expression in A549 cells and
isolation of microsomes
Preparation of A549 cells and determination of mPGES-1 activ-
ity was performed as described previously.14 In brief, A549 cells
(2  106 cells in 20 ml medium) were plated in 175 cm2 ﬂasks
and incubated for 16 h at 37 C and 5% CO2. Subsequently, the cul-
ture medium was replaced by fresh DMEM/high glucose (4.5 g/l)
medium containing FCS (2%, v/v). In order to induce mPGES-1
expression, IL-1b (1 ng/ml) was added, and cells were incubated
for another 72 h. Thereafter, cells were detached with trypsin/
EDTA, washed with PBS, and frozen in liquid nitrogen. Ice-cold
homogenization buffer (0.1 M potassium phosphate buffer pH
7.4, 1 mM phenylmethanesulfonylﬂuoride, 60 lg/ml soybean tryp-
sin inhibitor, 1 lg/ml leupeptin, 2.5 mM glutathione, and 250 mM
sucrose) was added, and after 15 min, cells were resuspended and
sonicated on ice (3  20 s). The homogenate was subjected to dif-
ferential centrifugation at 10,000g for 10 min and 174,000g for
1 h at 4 C. The pellet (microsomal fraction) was resuspended in
1 ml homogenization buffer, and the total protein concentration
was determined by Coomassie protein assay. Microsomal mem-
brane fractions were stored at 80 C for several weeks.
4.2.4. Determination of PGE2 synthase activity in microsomes
of A549 cells
Microsomal membranes were diluted in potassium phosphate
buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione to give a ﬁnal
concentration of 50 lg/ml. Test compounds or vehicle (DMSO at a
ﬁnal concentration of 1%) were added, and after 15 min at 4 C, the
reaction (100 ll total volume) was initiated by addition of PGH2
(20 lM, ﬁnal concentration). After 1 min at 4 C, the reaction was
terminated using stop solution (100 ll; 40 mM FeCl2, 80 mM citricacid, and 10 lM of 11b-PGE2). PGE2 was separated by solid phase
extraction on reversed phase (RP)-C18 material using acetonitrile
(200 ll) as eluent, and analyzed by RP-HPLC (30% acetonitrile
aq + 0.007% TFA (v/v), Nova-Pak C18 column, 5  100 mm, 4 lm
particle size, ﬂow rate 1 ml/min) with UV detection at 195 nm as
previously described.14 11b-PGE2 was used as internal standard
to quantify PGE2 product formation by integration of the area un-
der the peaks. IC50 values were assessed by ﬁve determinations at
compound concentrations of 0.01, 0.03, 0.1, 0.3, 1, 3, 10, and
30 lM.
4.2.5. Activity assays of isolated COX-1 and -2
Inhibition of the activities of isolated COX-1 and -2 was per-
formed as described.14 Brieﬂy, puriﬁed COX-1 (ovine, 50 units) or
COX-2 (human recombinant, 20 units) were diluted in 1 ml reaction
mixture containing 100 mM Tris buffer pH 8, 5 mM glutathione,
5 lMhemoglobin, and 100 lMEDTA at 4 C and pre-incubatedwith
the test compounds for 5 min. Sampleswere pre-warmed for 60 s at
37 C, and AA (5 lM for COX-1, 2 lM for COX-2) was added to start
the reaction. After 5 min at 37 C, 12-HHT was extracted and then
analyzed by HPLC.
4.2.6. Determination of PGE2 and 6-keto PGF1a formation in
intact A549 cells
IL-1b-treated A549 cells were cultured as described above.
4  106 cells per ml PBS containing CaCl2 (1 mM) were pre-incu-
bated with test compounds or vehicle (DMSO, never exceeding a ﬁ-
nal concentration of 0.3%) at 37 C for 10 min, and PGE2 formation
was started by addition of ionophore A23187 (5-methylamino-2-
[[(2S,3R,5R,8S,9S)-3,5,9-trimethyl-2-[(2S)-1-oxo-1-(1H-pyrrol-2-yl)-
propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzo-
oxazole-4-carboxylic acid, 2.5 lM), AA (1 lM), and [3H]AA
(18.4 kBq). The reaction was stopped after 15 min on ice. After cen-
trifugation (800g, 5 min, 4 C), the supernatant was acidiﬁed (pH 3)
by addition of citric acid (20 ll, 2 M), and the internal standard
11b-PGE2 (2 nmol) was added. Radiolabeled PGE2 was separated
by RP-18 solid phase extraction and HPLC analysis as described
above. The amount of 11b-PGE2 was quantiﬁed by integration of
the area under the eluted peaks. For quantiﬁcation of radiolabeled
PGE2, fractions (0.5 ml) were collected and mixed with Ultima
GoldTM XR (2 ml) for liquid scintillation counting in a LKB Wallac
1209 Rackbeta Liquid Scintillation Counter.
For determination of 6-keto PGF1a, 5  106 cells, resuspended in
1 ml PBS containing CaCl2 (1 mM), were pre-incubated with the
indicated compounds or celecoxib (4-(5-(4-methylphenyl)-3-(tri-
ﬂuoromethyl)pyrazol-1-yl)benzenesulfonamide, 5 lM) for 15 min
at 37 C, and 6-keto PGF1a formation was initiated by addition of
AA (30 lM). After 15 min at 37 C, the reaction was stopped on
ice. Cells were centrifuged (300g, 5 min, 4 C), and the amount of
released 6-keto PGF1a was assessed by ELISA using a monoclonal
antibody against 6-keto PGF1a according to the protocol described
by Yamamoto et al.39 For the ELISA, the monoclonal antibody
(0.2 lg/200 ll) was coated on microtiter plates via a goat anti-
mouse immunoglobulin G antibody. 6-Keto PGF1a (15 lg) was
linked to bacterial b-galactosidase (0.5 mg), and the enzyme activ-
ity bound to the antibody was determined in an ELISA reader at
550 nm (reference wavelength: 630 nm) using chlorophenol-
red-b-D-galactopyranoside (CPRG, Roche Diagnostic GmbH) as
substrate.
4.2.7. Determination of COX-1 product formation in washed
platelets
Freshly isolated platelets (108/ml PBS) were supplemented with
1 mM CaCl2 and pre-incubated with the indicated agents (ﬁnal
DMSO concentration 6 0.3%) for 10 min at room temperature. After
addition of AA (5 lM) and further incubation for 5 min at 37 C, the
7932 A. Koeberle et al. / Bioorg. Med. Chem. 17 (2009) 7924–7932COX-1 product 12-HHT was extracted and then analyzed by HPLC
as described.40
4.2.8. Carrageenan-induced pleurisy in rats and paw edema in
mice
For analysis of pleurisy, test compounds were given ip to male
Wistar Han rats (220–230 g) 30 min before carrageenan. Rats were
anaesthetized and k-carrageenan was injected into the pleural cav-
ity. After four hours, the exudatewas removed, and the amount was
measured. Inﬁltrated leukocytes in the exudate were counted by
light microscopy after vital trypan blue staining. The amount of
PGE2 and6-ketoPGF1a in the exudatewas assayedby radioimmuno-
assay and enzyme immunoassay, respectively. The results are ex-
pressed as nanogramsper rat and represent themean ± SE of 10 rats.
For analysis of paw edema, test compounds were given ip to
male adult CD1 mice 30 min before carrageenan. Each group of
animals received subplantar administration of saline (0.05 ml) or
k-carrageenan 1% type IV (w/v) (0.05 ml) in saline. The paw was
immerged in the measurement chamber and the volume was mea-
sured by using a special hydropletismometer immediately before
subplantar injection and 2, 4, and 6 h thereafter. The assessment
of paw volume was always performed in double blind. More meth-
odological details can be found in the Supplementary data.
4.2.9. Statistics
Data are expressed as mean ± SE. IC50 values were graphically
calculated from averaged measurements at ﬁve different concen-
trations of the compounds (0.01–33 lM) using SIGMAPLOT 9.0 (Systat
Software Inc., San Jose, USA). The program GRAPHPAD INSTAT (Graphpad
Software Inc., San Diego, CA) was used for statistical comparisons.
Statistical evaluation of the data was performed by one-way ANO-
VAs for independent or correlated samples followed by Tukey HSD
post-hoc tests. Where appropriate, Student’s t test for paired and
correlated samples was applied. A P-value of <0.05 (*) was consid-
ered signiﬁcant.
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